Interferon-γ controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder
Brain · 04.04.2024 · 147 (4) · 1344-1361
DOI: 10.1093/brain/awad373 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 01.11.2023. Verfasst von Gabriel Arellano und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. Hauptthemen laut MEDLINE: Neuromyelitis Optica. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIAID NIH HHS, NIH HHS.
Abstract (Originalsprache)
Neuromyelitis optica spectrum disorder (NMOSD) is a CNS autoimmune inflammatory disease mediated by T helper 17 (Th17) and antibody responses to the water channel protein, aquaporin 4 (AQP4), and associated with astrocytopathy, demyelination and axonal loss. Knowledge about disease pathogenesis is limited and the search for new therapies impeded by the absence of a reliable animal model. In our work, we determined that NMOSD is characterized by decreased IFN-γ receptor signalling and that IFN-γ depletion in AQP4201–220-immunized C57BL/6 mice results in severe clinical disease resembling human NMOSD. Pathologically, the disease causes autoimmune astrocytic and CNS injury secondary to cellular and humoral inflammation. Immunologically, the absence of IFN-γ allows for increased expression of IL-6 in B cells and activation of Th17 cells, and generation of a robust autoimmune inflammatory response. Consistent with NMOSD, the experimental disease is exacerbated by administration of IFN-β, whereas repletion of IFN-γ, as well as therapeutic targeting of IL-17A, IL-6R and B cells, ameliorates it. We also demonstrate that immune tolerization with AQP4201–220-coupled poly(lactic-co-glycolic acid) nanoparticles could both prevent and effectively treat the disease. Our findings enhance the understanding of NMOSD pathogenesis and provide a platform for the development of immune tolerance-based therapies, avoiding the limitations of the current immunosuppressive therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
- Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
- Department of Biology, Loyola University Chicago, Chicago, IL 60660, USA.
- COUR Pharmaceutical Development Company, Inc., Northbrook, IL 60077, USA.
ORCID-Profile: Stephen D Miller
Förderung
- NINDS NIH HHS
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
- Johnnie Walkers MS Foundation
- Amy and David Fulton Foundation
- Crammer Family Foundation
- Thomas and Deige McLaughlin Foundation
Zitieren
APA
Arellano, G., Loda, E., Chen, Y., Neef, T., Cogswell, A. C., Primer, G., Joy, G., Kaschke, K., Wills, S., Podojil, J. R., Popko, B., Balabanov, R., & Miller, S. D. (2024). Interferon-γ controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder. Brain, 147(4), 1344-1361. https://doi.org/10.1093/brain/awad373
Vancouver
Arellano G, Loda E, Chen Y, Neef T, Cogswell AC, Primer G, et al. Interferon-γ controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder. Brain. 2024;147(4):1344-1361. doi:10.1093/brain/awad373
BibTeX
@article{Arellano2024,
author = {Arellano, Gabriel and Loda, Eileah and Chen, Yanan and Neef, Tobias and Cogswell, Andrew C and Primer, Grant and Joy, Godwin and Kaschke, Kevin and Wills, Samantha and Podojil, Joseph R and Popko, Brian and Balabanov, Roumen and Miller, Stephen D},
title = {Interferon-γ controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder},
journal = {Brain},
year = {2024},
volume = {147},
number = {4},
pages = {1344--1361},
doi = {10.1093/brain/awad373}
}
EUVIMED